Concentrix Corporation reported $10.00B of revenue over the trailing twelve months, +3.9% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $10.00B (to Q2 2026). Net income: −$1.31B, trailing twelve months to Q2 2026. Free cash flow: $514M, trailing twelve months to Q2 2026. Operating margin: −9.9%, trailing twelve months to Q2 2026.

CNXCConcentrix Corporation

Technology

$25.95-53% 1Y

$25.95

$21.9252 weeks$53.93

CNXC as reported

Concentrix Corporation reported $10.00B of revenue over the trailing twelve months, +3.9% on the year before. 11 reported series are charted on this page, each one as filed.

$10.00B

Revenue, trailing twelve months · to Q2 2026 · +3.9% against the twelve months before

Net income: −$1.31B
Net income · −637% year on year · trailing twelve months to Q2 2026
Free cash flow: $514M
Free cash flow · +5.9% year on year · trailing twelve months to Q2 2026
Operating margin: −9.9%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for CNXC, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$10.00B	+3.9%	Q2 2026
Net income	−$1.31B	−637%	Q2 2026
EPS	−$20.84	−674%	Q2 2026
Gross margin	34%	n/a	Q2 2026
Operating margin	−9.9%	n/a	Q2 2026
Net margin	−13%	n/a	Q2 2026
ROE	−34%	n/a	Q2 2026
ROA	−8.6%	n/a	Q2 2026
ROIC	−6.7%	n/a	Q2 2026
Free cash flow	$514M	+5.9%	Q2 2026
P/E	12.0	n/a	Q3 2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.